Related Experiment Video

Updated: Jan 6, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Update on Antithrombotic Therapy after Percutaneous Coronary Intervention

Yuichi Saito1,2, Yoshio Kobayashi1

  • 1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan.

Internal Medicine (Tokyo, Japan)
|October 8, 2019
PubMed

Insights

Optimizing antithrombotic therapy after percutaneous coronary intervention (PCI) is crucial. This review examines balancing clot prevention and bleeding risk with dual antiplatelet therapy and anticoagulation in coronary artery disease patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention (PCI) is standard for angina and acute coronary syndrome.
  • Antithrombotic therapy is essential post-PCI to prevent ischemic events.
  • Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces stent thrombosis.

Purpose of the Study:

  • To review current evidence on antithrombotic therapy in patients with coronary artery disease undergoing PCI.
  • To address controversies regarding DAPT duration and agent choice.
  • To discuss challenges of combined oral anticoagulation and antiplatelet therapy.

Main Methods:

  • Literature review of current evidence.
  • Analysis of studies on antithrombotic regimens post-PCI.
  • Synthesis of data on balancing thrombotic and bleeding risks.

Main Results:

  • DAPT decreases stent-related thrombotic risks but optimal strategies remain debated.
  • Choice of P2Y12 inhibitor and therapy duration are controversial.
  • Integrating oral anticoagulation with antiplatelet therapy presents complex clinical challenges.

Conclusions:

  • Optimal antithrombotic regimen post-PCI requires balancing efficacy and safety.
  • Further research is needed to clarify optimal duration and agent selection for DAPT.
  • Careful consideration of bleeding risk is paramount when combining anticoagulation and antiplatelet therapy.

Keywords:
antithrombotic therapydual antiplatelet therapypercutaneous coronary intervention

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

497
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
194
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
215
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
202
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
267
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K